Hongbo Lu

Partner at Vivo Capital

Hongbo is a Managing Partner at Vivo Capital, leading its public and innovation private investment strategies. Previously she was a Managing Partner at Lilly Asia Ventures (LAV) and contributed meaningfully to the growth and expansion of the platform during 2017-2020. Prior to LAV, Hongbo was a Managing Director at OrbiMed and led the firm’s entry in public investments in Asia. She was one of the first few biotech specialists investing in Asia healthcare public equities since 2011. Among private investments, Hongbo served on the boards of Turning Point Therapeutics (TPTX), CrownBio (6554.TT, acquired by JSR), Avedro (AVDR, acquired by Glaukos), PINS, Avistone, Rgenta, as well as served as a founding board member of ADARx, Elpiscience, Geneception, MedtecX, Terns, Ronovo, Ribox, and Visirna since inception. Hongbo started her career as a bench scientist, before transitioning into biotech equity research at Piper Jaffrays in early 2000. Hongbo holds a PhD in Bioengineering from University of Washington, MBA from Haas School of Business, UC Berkeley, and is a distinguished graduate of Tsinghua University.